FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385705842> ?p ?o ?g. }

• W4385705842 endingPage "e2521759" @default.
• W4385705842 startingPage "e2521759" @default.
• W4385705842 abstract "Background: Chronic myelomonocytic leukemia (CMML) is a hematologic disorder with high risk of transformation to acute myeloid leukemia (AML). The clinical outcomes of patients with CMML whose disease progresses to AML remains dismal. Identification of disease subtypes of AML after CMML is necessary to inform development of future therapies. Aims: We sought to analyze the distinct patterns of CMML transformation and dissect their genomic determinants, clonal architecture, and clinical outcomes with distinct therapeutic modalities to identify disease subsets with distinct clinicopathological features. Methods: We evaluated all consecutive patients (pts) with AML evolving from antecedent CMML treated at our institution from 2001 to 2022. Based on blast morphology and immunophenotype cases were classified as monocytic (≥20% monoblasts and/or promonocytes or ≥20% CD14+/CD64+ blasts with otherwise non-monocytic morphology), myeloid (≥20% blasts not meeting criteria for monocytic) or erythroid (≥80% immature erythroid precursors positive for CD71, E-cadherin and/or CD235a). The Kaplan-Meier method was used to estimate the median overall (OS) and event-free (EFS) survival. Cox proportional hazards regression was used to study association of clinical or treatment variables with survival. Results: A total of 189 pts were identified: 101 (53%) with monocytic (Mo-AML), 85 (45%) with myeloid (My-AML) and 3 (2%) with erythroid leukemia (Ery-AML). Median age was 71 years (range 28-90) with male predominance (66%). Compared to My-AML, pts with Mo-AML had higher median white blood cell count (23.5 vs 6.0 x109/L, p<0.001), peripheral blood (31% vs 12%, p<0.001) and bone marrow monocyte % (12% vs 6%, p<0.001). Mo-AML was associated with higher frequency of CD56 (51% vs 21%, p<0.001), and lower CD34 (30% vs 89%, p<0.001), CD38 (83% vs 97%, p=0.006) and CD117 (35% vs 87%, p<0.001) blast positivity. Pts with Mo-AML were more likely to have CBL (37% vs 7%, p=0.005), SRSF2 (57% vs 27%, p=0.018) and RAS pathway (BRAF, CBL, KRAS, NRAS, NF1, PTPN11) mutations (85% vs 57%, p=0.006) while CEBPA mutations were more common among My-AML (23% vs 3%, p=0.023) (Fig 1A-B). Median VAF of TET2 mutations was higher among Mo-AML (45% vs 39%, p=0.033). Pts with Mo-AML were defined by concurrent TET2, SRSF2 and RAS pathway mutations (43% vs 13%, p=0.01), compared to My-AML, and more frequently had RAS pathway mutations as dominant clones (56% vs 27%, p=0.013). Pts with Mo-AML were more likely to evolve from SRSF2 (58% vs 27%, p=0.025) and TET2 (65% vs 40%, p=0.038) mutant CMML, particularly with RAS pathway or ASXL1 mutations (Fig 1C). Cytogenetic evolution was observed in 42/107 (39%) pts, with new previously undetectable somatic mutations or expansion of pre-existing clones being observed in 28/42 (82%) and 14/42 (41%) pts, respectively. Pts with Mo-AML acquired higher number of balanced/unbalanced translocations and clonal evolution of RAS signaling mutations (81% vs 33%, p=0.005) (Fig 1D). With a median follow up of 49.5 months, the median OS and EFS was 5.9 and 2.6 months, respectively. Trends to improved EFS with venetoclax and cladribine/clofarabine containing regimens were observed in My-AML and Mo-AML, respectively (Fig 1E-F). Summary/Conclusion: Our data support that disease transformation in CMML can occur through three distinct phenotypic trajectories characterized by specific genomic profiles and clonal evolution. This sets the basis for potential future studies to develop phenotype-specific targeted novel therapeutics.Keywords: Genomics, CMML, Acute monoblastic leukemia, Acute myeloid leukemia" @default.
• W4385705842 created "2023-08-10" @default.
• W4385705842 creator A5000750846 @default.
• W4385705842 creator A5010786159 @default.
• W4385705842 creator A5013391732 @default.
• W4385705842 creator A5020340537 @default.
• W4385705842 creator A5028081179 @default.
• W4385705842 creator A5028622482 @default.
• W4385705842 creator A5029750735 @default.
• W4385705842 creator A5030063957 @default.
• W4385705842 creator A5030500582 @default.
• W4385705842 creator A5035605515 @default.
• W4385705842 creator A5044987134 @default.
• W4385705842 creator A5049385583 @default.
• W4385705842 creator A5051949215 @default.
• W4385705842 creator A5055045706 @default.
• W4385705842 creator A5056317446 @default.
• W4385705842 creator A5059373442 @default.
• W4385705842 creator A5059600583 @default.
• W4385705842 creator A5061026876 @default.
• W4385705842 creator A5085006230 @default.
• W4385705842 creator A5088307376 @default.
• W4385705842 creator A5091492845 @default.
• W4385705842 date "2023-08-01" @default.
• W4385705842 modified "2023-10-15" @default.
• W4385705842 title "P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA" @default.
• W4385705842 doi "https://doi.org/10.1097/01.hs9.0000968892.25217.59" @default.
• W4385705842 hasPublicationYear "2023" @default.
• W4385705842 type Work @default.
• W4385705842 citedByCount "0" @default.
• W4385705842 crossrefType "journal-article" @default.
• W4385705842 hasAuthorship W4385705842A5000750846 @default.
• W4385705842 hasAuthorship W4385705842A5010786159 @default.
• W4385705842 hasAuthorship W4385705842A5013391732 @default.
• W4385705842 hasAuthorship W4385705842A5020340537 @default.
• W4385705842 hasAuthorship W4385705842A5028081179 @default.
• W4385705842 hasAuthorship W4385705842A5028622482 @default.
• W4385705842 hasAuthorship W4385705842A5029750735 @default.
• W4385705842 hasAuthorship W4385705842A5030063957 @default.
• W4385705842 hasAuthorship W4385705842A5030500582 @default.
• W4385705842 hasAuthorship W4385705842A5035605515 @default.
• W4385705842 hasAuthorship W4385705842A5044987134 @default.
• W4385705842 hasAuthorship W4385705842A5049385583 @default.
• W4385705842 hasAuthorship W4385705842A5051949215 @default.
• W4385705842 hasAuthorship W4385705842A5055045706 @default.
• W4385705842 hasAuthorship W4385705842A5056317446 @default.
• W4385705842 hasAuthorship W4385705842A5059373442 @default.
• W4385705842 hasAuthorship W4385705842A5059600583 @default.
• W4385705842 hasAuthorship W4385705842A5061026876 @default.
• W4385705842 hasAuthorship W4385705842A5085006230 @default.
• W4385705842 hasAuthorship W4385705842A5088307376 @default.
• W4385705842 hasAuthorship W4385705842A5091492845 @default.
• W4385705842 hasBestOaLocation W43857058421 @default.
• W4385705842 hasConcept C126322002 @default.
• W4385705842 hasConcept C143998085 @default.
• W4385705842 hasConcept C196166836 @default.
• W4385705842 hasConcept C203014093 @default.
• W4385705842 hasConcept C2777928532 @default.
• W4385705842 hasConcept C2778461978 @default.
• W4385705842 hasConcept C2778729363 @default.
• W4385705842 hasConcept C2779282312 @default.
• W4385705842 hasConcept C2780007613 @default.
• W4385705842 hasConcept C2780817109 @default.
• W4385705842 hasConcept C2781087989 @default.
• W4385705842 hasConcept C553184892 @default.
• W4385705842 hasConcept C71924100 @default.
• W4385705842 hasConceptScore W4385705842C126322002 @default.
• W4385705842 hasConceptScore W4385705842C143998085 @default.
• W4385705842 hasConceptScore W4385705842C196166836 @default.
• W4385705842 hasConceptScore W4385705842C203014093 @default.
• W4385705842 hasConceptScore W4385705842C2777928532 @default.
• W4385705842 hasConceptScore W4385705842C2778461978 @default.
• W4385705842 hasConceptScore W4385705842C2778729363 @default.
• W4385705842 hasConceptScore W4385705842C2779282312 @default.
• W4385705842 hasConceptScore W4385705842C2780007613 @default.
• W4385705842 hasConceptScore W4385705842C2780817109 @default.
• W4385705842 hasConceptScore W4385705842C2781087989 @default.
• W4385705842 hasConceptScore W4385705842C553184892 @default.
• W4385705842 hasConceptScore W4385705842C71924100 @default.
• W4385705842 hasIssue "S3" @default.
• W4385705842 hasLocation W43857058421 @default.
• W4385705842 hasLocation W43857058422 @default.
• W4385705842 hasOpenAccess W4385705842 @default.
• W4385705842 hasPrimaryLocation W43857058421 @default.
• W4385705842 hasRelatedWork W2031541998 @default.
• W4385705842 hasRelatedWork W2080925159 @default.
• W4385705842 hasRelatedWork W2097160518 @default.
• W4385705842 hasRelatedWork W2134525239 @default.
• W4385705842 hasRelatedWork W2150998544 @default.
• W4385705842 hasRelatedWork W2952057202 @default.
• W4385705842 hasRelatedWork W2979755880 @default.
• W4385705842 hasRelatedWork W2980824909 @default.
• W4385705842 hasRelatedWork W2989212106 @default.
• W4385705842 hasRelatedWork W4256273447 @default.
• W4385705842 hasVolume "7" @default.
• W4385705842 isParatext "false" @default.
• W4385705842 isRetracted "false" @default.
• W4385705842 workType "article" @default.